April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fewer Moles May Be Related to Aggressive Melanoma
August 21st 2015It is well known that having multiple moles (ie, >50) is a risk factor for developing melanoma. A new study shows, however, that melanoma can also develop in people with fewer than 50 moles, and when it does, it typically has a more aggressive course.
Read More
FDA Delays Decision for Frontline Nivolumab
August 13th 2015The review period for frontline nivolumab (Opdivo), in patients who have advanced melanoma, recently received an extension of three months by the FDA, in order to allow ample time for review of the additional data submitted by Bristol-Myers Squibb (BMS)
Read More
Sonidegib Approved by the FDA for Basal Cell Carcinoma
July 24th 2015Hedgehog inhibitor sonidegib (Odomzo) was recently approved by the FDA for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation, or for those not eligible for these treatments.
Read More
Study of Vemurafenib Combined With a MEK Inhibitor
July 23rd 2015Anna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the study of vemurafenib combined with a MEK inhibitor.
Watch
Breakthrough Designation Granted to BRAF/MEK Combo for BRAF V600 NSCLC
July 23rd 2015Breakthrough therapy designation has been granted by the US Food and Drug Adminstration (FDA) to the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) as treatment for patients with BRAF V600E-mutant non–small cell lung cancer
Read More
Pembrolizumab (Keytruda) Approved by European Commission for Advanced Melanoma
July 23rd 2015The PD-1 inhibitor pembrolizumab (Keytruda) was recently approved by the European Commission for the treatment of adult patients who have unresectable or metastatic melanoma in the first-line and previously treated settings, based on data from three clinical trials that evaluated the medication in over 1500 patients.
Read More
Case Shows Dramatic Antitumor Effects With Immunotherapy in Melanoma
July 23rd 2015A letter to the editor in the New England Journal of Medicine from notable researchers at Memorial Sloan Kettering reported a case of complete remission of metastatic melanoma in a patient treated with single doses of ipiliumab and nivolumab.
Read More
PFS and Safety With Nivolumab Plus Ipilimumab in Advanced Melanoma
July 17th 2015Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI).
Read More
Epigenetic-Active Agents May Improve Sensitivity to Temozolomide in Melanoma
July 16th 2015Using treatments that target epigenetic pathways, including the DNA methyltransferase inhibitor decitabine and the histone deacetylase (HDAC) inhibitor panobinostat, investigators hoped to improve the sensitivity of melanoma cells to the alkylating agent temozolomide.
Read More
Melanoma Intrinsic-catenin Signaling on Immune Exclusion and Resistance to Immunotherapies
June 30th 2015Stefani Spranger, PhD, post-doctoral fellow, Department of Pathology, The University of Chicago Medicine, discusses the significance of melanoma intrinsic β-catenin signaling on immune exclusion and resistance to immunotherapies.
Read More
Ipilimumab Combined With Nivolumab for the Treatment of Patients With Melanoma
June 30th 2015Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.
Watch
Afatinib Versus Erlotinib in Advanced SCC of the Lung
June 24th 2015Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.
Watch
Nivolumab Regimen Significantly Improves PFS in Frontline Melanoma
June 2nd 2015Frontline nivolumab more than doubled progression-free survival (PFS), both as monotherapy and combined with ipilimumab compared with ipilimumab alone in patients with advanced melanoma, according to results from the phase III CheckMate-067 trial.
Read More
BRAF/MEK Combo Shows Overall Survival Benefit at 2 Years in Melanoma Patients
June 1st 2015Patients with BRAF-mutant late-stage melanoma derive a lasting overall survival (OS) benefit from treatment with the combination of dabrafenib and trametinib compared with dabrafenib and placebo, according to the final results from the COMBI-d phase III double-blinded trial.
Read More
Frontline Nivolumab Granted FDA Priority Review in Melanoma
April 30th 2015The PD-1 inhibitor nivolumab (Opdivo) has been has been assigned priority review designation from the US Food and Drug Administration (FDA) as a treatment for previously untreated patients with unresectable or metastatic melanoma.
Read More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanoma
April 23rd 2015Results from the phase II, double-blind CheckMate-069 clinical trial showed unprecedented response rates with ipilimumab combined with nivolumab in previously treated patients with metastatic melanoma.
Read More